These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 32339215)

  • 1. Clinical Impact of Renin-angiotensin System Inhibitors on In-hospital Mortality of Patients With Hypertension Hospitalized for Coronavirus Disease 2019.
    Tedeschi S; Giannella M; Bartoletti M; Trapani F; Tadolini M; Borghi C; Viale P
    Clin Infect Dis; 2020 Jul; 71(15):899-901. PubMed ID: 32339215
    [No Abstract]   [Full Text] [Related]  

  • 2. Renin-Angiotensin-Aldosterone System Inhibitors Impact on COVID-19 Mortality: What's Next for ACE2?
    Patel AB; Verma A
    Clin Infect Dis; 2020 Nov; 71(16):2129-2131. PubMed ID: 32442259
    [No Abstract]   [Full Text] [Related]  

  • 3. Inquiring Into Benefits of Independent Activation of Nonclassical Renin-angiotensin System in the Clinical Prognosis and Reduction of COVID-19 Mortality.
    Álvarez-Aragón LM; Cuesta-Muñoz AL; Álvarez-López I
    Clin Infect Dis; 2020 Jul; 71(15):894-895. PubMed ID: 32266375
    [No Abstract]   [Full Text] [Related]  

  • 4. Renin-Angiotensin-Aldosterone System Inhibitors and Outcome in Patients With SARS-CoV-2 Pneumonia: A Case Series Study.
    Conversano A; Melillo F; Napolano A; Fominskiy E; Spessot M; Ciceri F; Agricola E
    Hypertension; 2020 Aug; 76(2):e10-e12. PubMed ID: 32383626
    [No Abstract]   [Full Text] [Related]  

  • 5. RAAS Inhibitors and Risk of Covid-19.
    Sriram K; Loomba R; Insel PA
    N Engl J Med; 2020 Nov; 383(20):1991-1992. PubMed ID: 33108103
    [No Abstract]   [Full Text] [Related]  

  • 6. RAAS Inhibitors and Risk of Covid-19.
    Angeli F; Verdecchia P; Reboldi G
    N Engl J Med; 2020 Nov; 383(20):1990-1991. PubMed ID: 33108102
    [No Abstract]   [Full Text] [Related]  

  • 7. Renin-angiotensin-aldosterone system inhibitors to treat COVID-19?
    Henry RA
    CMAJ; 2020 Jun; 192(26):E728. PubMed ID: 32601254
    [No Abstract]   [Full Text] [Related]  

  • 8. [Hypertension, RAAS blockade and risk in COVID-19 patients].
    Spaak J; Kahan T
    Lakartidningen; 2020 Jun; 117():. PubMed ID: 32594472
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular disease and the impact of COVID-19.
    Yoganathan A; Sajjad MS; Harky A
    J Card Surg; 2020 Aug; 35(8):2113. PubMed ID: 32542799
    [No Abstract]   [Full Text] [Related]  

  • 10. COVID-19: The heart of the issue.
    Woodward B; Kermali M
    J Card Surg; 2020 Aug; 35(8):2112. PubMed ID: 32542802
    [No Abstract]   [Full Text] [Related]  

  • 11. Decreased Mortality of COVID-19 With Renin-Angiotensin-Aldosterone System Inhibitors Therapy in Patients With Hypertension: A Meta-Analysis.
    Guo X; Zhu Y; Hong Y
    Hypertension; 2020 Aug; 76(2):e13-e14. PubMed ID: 32458694
    [No Abstract]   [Full Text] [Related]  

  • 12. Use of Renin-Angiotensin System Blockers During the COVID-19 Pandemic: Early Guidance and Evolving Evidence.
    Turgeon RD; Zieroth S; Bewick D; Chow CM; Clarke B; Cowan S; Fordyce CB; Fournier A; Gin K; Gupta A; Hardiman S; Jackson S; Lau B; Leong-Poi H; Mansour S; Marelli A; Quraishi AR; Roifman I; Ruel M; Sapp J; Singh G; Small G; Virani S; Wood DA; Krahn A
    Can J Cardiol; 2020 Aug; 36(8):1180-1182. PubMed ID: 32502522
    [No Abstract]   [Full Text] [Related]  

  • 13. Obesity and COVID-19.
    Azzolino D; Cesari M
    Front Endocrinol (Lausanne); 2020; 11():581356. PubMed ID: 33101213
    [No Abstract]   [Full Text] [Related]  

  • 14. COVID-19 Interference with Renin-Angiotensin System in the Context of Heart Failure.
    Siniorakis E; Arvanitakis S; Nikolopoulos I; Elkouris M
    mBio; 2020 May; 11(3):. PubMed ID: 32444383
    [No Abstract]   [Full Text] [Related]  

  • 15. Age and Multimorbidity Predict Death Among COVID-19 Patients: Results of the SARS-RAS Study of the Italian Society of Hypertension.
    Iaccarino G; Grassi G; Borghi C; Ferri C; Salvetti M; Volpe M;
    Hypertension; 2020 Aug; 76(2):366-372. PubMed ID: 32564693
    [TBL] [Abstract][Full Text] [Related]  

  • 16. What Kind of Evidence Is Needed to Dictate Practice Regarding Inhibitors of the Renin-Angiotensin System in COVID-19?
    Elijovich F; Laffer CL
    Hypertension; 2020 Sep; 76(3):665-669. PubMed ID: 32783759
    [No Abstract]   [Full Text] [Related]  

  • 17. Position Paper of the Department of Hypertension of the Brazilian Society of Nephrology: Use of renin-angiotensin system blockers during the course of Covid-19 infection.
    Rodrigues CIS
    J Bras Nefrol; 2020 Aug; 42(2 suppl 1):47-48. PubMed ID: 32877500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renin-angiotensin system inhibitors in the COVID-19 pandemic: consequences of antihypertensive drugs.
    Ruilope LM; Tamargo J; Ruiz-Hurtado G
    Eur Heart J; 2020 Jun; 41(22):2067-2069. PubMed ID: 32498078
    [No Abstract]   [Full Text] [Related]  

  • 19. Controversial Relationship Between Renin-Angiotensin System Inhibitors and Severity of COVID-19: Announcing a Large Multicentre Case-Control Study in Italy.
    Di Castelnuovo A; De Caterina R; de Gaetano G; Iacoviello L
    Hypertension; 2020 Aug; 76(2):312-313. PubMed ID: 32383624
    [No Abstract]   [Full Text] [Related]  

  • 20. Sarcopenia and COVID-19: A Manifold Insight on Hypertension and the Renin Angiotensin System.
    Ekiz T; Kara M; Özcan F; Ricci V; Özçakar L
    Am J Phys Med Rehabil; 2020 Oct; 99(10):880-882. PubMed ID: 32657817
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.